

発表（国際）

1. Mechanism analysis of molecular incompatibility in protein C-EPCR coagulation system for pig to human xenotransplantation. Y. Miwa, K. Iwasaki, S. Suzuki, D. Fuchimoto, M. Iwamoto, A. Onishi, T. Kobayashi IXA2018 Baltimore (USA)/2017 9/20-23 Oral
2. Differential response of allo-/xeno-reactive CD4 T-cells against MHC expressed in endothelial cells in the presence of HLA, ABO, and xeno (Gal and nonGal) antibody. K. Iwasaki, Y. Miwa, H. Hamana, H. Kishi, A. Muraguchi, T. Kobayashi IXA2018 Baltimore (USA) 2017/9/20-23 Oral
3. Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome. Y. Watarai, S. Narumi, M. Okada, R. Kimura, K. Hatazoe, K. Futamura, T. Yamamoto, T. Hiramitsu, M. Tsujita, N. Goto, T. Kobayashi. ATC2017 Chicago (USA) 2017/4/29-5/3 Poster
4. One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial. Y. Hidaka, S. Yamanaga, M. Toyoda, S. Narumi, Y. Watarai, T. Kobayashi. ATC2017 Chicago (USA) 2017/4/29-5/3 Poster
5. Inferior 10-Year Graft and Patient Survival After End-to-Side Reconstruction for Two Renal Arteries in Living Donor Renal Transplantation. S. Yamanaga, A. Posselt, C. Freise, C. Niemann, A. Rosario, D. Fernandez, T. Kobayashi, A. Ahearn, M. Tavakol, S.-M. Kang. ATC2017 Chicago (USA) 2017/4/29-5/3 Poster

6. Avoidance or Reduction of Rituximab Might Improve Clinical Outcomes in ABO-Incompatible Renal Transplantation: Advantages and Disadvantages of Rituximab. M. Okada, Y. Watarai, K. Iwasaki, K. Murotani, T. Hiramitsu, M. Tsujita, N. Goto, S. Narumi, T. Kobayashi ATC2017 Chicago (USA) 2017/4/29-5/3 Poster
7. Inferior Graft and Patient Survival After Living Donor Renal Transplantation of Negatively Selected Right Kidneys. S. Yamanaga, A. Posselt, C. Freise, C. Niemann, A. Rosario, D. Fernandez, T. Kobayashi, A. Ahearn, M. Tavakol, S.-M. Kang. ATC2017 Chicago (USA) 2017/4/29-5/3 Oral
8. When Does the Learning Curve End? A High-Volume Single Center Experience with Laparoscopic Donor Nephrectomy Over 16 Years. S. Yamanaga, A. Posselt, C. Freise, C. Niemann, A. Rosario, D. Fernandez, T. Kobayashi, A. Ahearn, M. Tavakol, S.-M. Kang ATC2017 Chicago (USA) 2017/4/29-5/3 Oral
9. Lower Incidence of DSA-Induced Chronic Antibody-Mediated Rejection in ABO-Incompatible Renal Transplantation. M. Okada, Y. Watarai, K. Iwasaki, K. Futamura, T. Hiramitsu, M. Tsujita, N. Goto, S. Narumi, T. Kobayashi ATC2017 Chicago (USA) 2017/4/29-5/3 Oral
10. ABO incompatibility might protect renal graft against chronic antibody-mediated rejection caused by de novo DSA. M. Okada, K. Futamura, K. Iwasaki, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, Y. Watarai, T. Kobayashi TTS 2016 Hong Kong (China) 2016/8/18-23 Oral

11. The preventative effect of anti-A/B antibody and mTOR-inhibitor on anti-HLA-DR antibody mediated complement dependent cytotoxicity. K. Iwasaki, Y. Miwa, K. Uchida, T. Kobayashi
TTS 2016 Hong Kong (China) 2016/8/18-23 Oral
12. Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients. Y. Watarai, M. Okada, K. Futamura, T. Nagai, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi. ATC2016 Boston (MA, USA) 2016/6/11-15 Poster
13. Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 7 Years Follow-Up. Y. Watarai, M. Okada, K. Futamura, T. Nagai, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi. ATC2016 Boston (MA, USA) 2016/6/11-15 Poster
14. Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up. Y. Watarai, M. Okada, K. Futamura, T. Nagai, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi. ATC2016 Boston (MA, USA) 2016/6/11-15 Poster
15. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody Mediated Kidney Allograft Injuries. T. Yamamoto, Y. Watarai, A. Takeda, M. Okada, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, K. Morozumi, K. Uchida, T. Kobayashi. ATC2016 Boston (MA, USA) 2016/6/11-15 Oral

16. The efficacy of eculizumab therapy for atypical hemolytic uremic syndrome recurrence and antibody mediated rejection progress after renal transplantation with preformed DSA. T. Yamamoto, Y. Watarai, M. Okada, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, A. Takeda, T. Kobayashi Transplantation Science Symposium (TSS) Asian Regional Meeting Tokyo (Japan) 2016/4/8-9 Poster
17. A kidney transplant recipient of recurrent MPO-ANCA vasculitis 9 years after transplantation concomitant with chronic antibody-mediated rejection. K. Horike, A. Takeda, T. Yamamoto, N. Goto, Y. Watarai, T. Kobayashi, T. Sato, A. Katayama, K. Morozumi Transplantation Science Symposium (TSS) Asian Regional Meeting Tokyo (Japan) 2016/4/8-9 Poster
18. mTOR alters the IFN γ -induced HLA-DR expression on endothelial cells. K. Iwasaki, Y. Miwa, K. Uchida, T. Kobayashi Transplantation Science Symposium (TSS) Asian Regional Meeting Tokyo (Japan) 2016/4/8-9 Poster
19. Study of proper expression level of human thrombomodulin in pig endothelial cell with effective anticoagulant activity and no bleeding tendency. Y. Miwa, K. Iwasaki, S. Suzuki, M. Iwamoto, A. Onishi, Y. Koderu, T. Kobayashi 2015 IPITA-IXA-CTS Joint Congress Melbourne (Australia) 2015/11/15-19 Oral
20. Human Endothelial Cell Activation through ERK by Non-Gal Antibody. K. Iwasaki, Y. Inanaga, Y. Miwa, M. Haneda, A. Onishi, H. Ogawa, T. Kobayashi 2015 IPITA-IXA-CTS Joint Congress Melbourne (Australia) 2015/11/15-19 Oral

21. ABO incompatibility and graft accommodation: Potential strategy to prevent acute/chronic antibody mediated rejection. T. Kobayashi ABO-I and anti-HLA hyperimmune patient. Pre-Meeting Symposia 2015 IPITA-IXA-CTS Joint Congress Melbourne (Australia) 2015/11/15-19 Symposium
22. Safety and efficacy of low dose and very low dose extended -release tacrolimus/MMF in de novo kidney transplant recipients. S Narum, Y Watarai, N Goto, T Hiramitsu, M Tsujita, T Yamamoto, M Okada, K Itoh, K Futamura, T Kobayashi 17th Congress of the European Society for Organ Transplantation Brussels (Belgium) 2015/9/13-16 poster
23. Impacts of mycophenolate mofetil addition to very low exposure everolimus and calcineurine inhibitor based immunosuppression in de novo kidney transplantation. S. Narumi, Y. Watarai, N. Goto, T. Hiramitsu, M. Tsujita, T. Yamamoto, M. Okada, K. Itoh, K. Futamura, T. Kobayashi 17th Congress of the European Society for Organ Transplantation Brussels (Belgium) 2015/9/13-16 poster
24. Rituximab sparing protocol for patients with low titers in ABO incompatible kidney transplantation. S. Narumi, Y. Watarai, N. Goto, T. Hiramitsu, M. Tsujita, T. Yamamoto, M. Okada, K. Itoh, K. Futamura, T. Kobayashi 17th Congress of the European Society for Organ Transplantation Brussels (Belgium) 2015/9/13-16 Oral
25. Efficacy of Rituximab Sparing Protocol for ABO Incompatible Renal Transplant in Patients With Low Titers. S. Narumi, Y. Watarai, N. Goto, T. Hiramitsu, T. Yamamoto, M. Tsujita, M. Okada, K. Futamura, A. Takeda, T. Kobayashi. ATC2015 Philadelphia (PA, USA) 2015/5/2~6 Poster

26. Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation. Y. Watarai, M. Okada, K. Futamura, K. Ito, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi. ATC2015 Philadelphia (PA, USA) 2015/5/2~6 Poster

27. Clinical Significance of Estimated DSA MFI Values at 1,000 C1q MFI for Differentiation Between Harmful and Harmless DSA. K. Horimi, T. Akaza, K. Kuroki, S. Sakamoto, Y. Matsuoka, Y. Watarai, S. Narumi, A. Katayama, K. Uchida, T. Kobayashi. ATC2015 Philadelphia (PA, USA) 2015/5/2~6 Poster

28. Favorable Results of ABO Incompatible Renal Transplantation Without B Cell Targeted Therapy: Advantages and Disadvantages of Rituximab Pretreatment. M. Okada, K. Futamura, K. Itou, T. Yamamoto, T. Hiramitsu, M. Tsujita, N. Goto, S. Narumi, Y. Watarai, A. Katayama, K. Uchida, T. Kobayashi. ATC2015 Philadelphia (PA, USA) 2015/5/2~6 Oral

29. De Novo DSA Would Not Necessarily Cause Graft Rejection After Renal Transplantation: Characteristics of DSA Developing Biopsy-Proven Chronic Antibody-Mediated Rejection. T. Yamamoto, Y. Watarai, A. Takeda, M. Okada, M. Tsujita, H. Takahisa, N. Goto, S. Narumi, T. Kobayashi. ATC2015 Philadelphia (PA, USA) 2015/5/2~6 Oral